Exhibit 99.1 Naarden, the Netherlands and Miami, USA; February 28, 2024 – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the fourth quarter and full year ended Dece ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-41562 NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in Its Charter) The Netherlands N/A (State or Other Jurisdiction ...

Exhibit 99.1 (*) Restated - see Note 10 The accompanying notes are an integral part of these consolidated financial statements. CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (UNAUDITED) CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE PROFIT OR LOSS (UNAUDITED) | | | For the six months ended June 30, | | | --- | --- | --- | --- | | | Note | 2023 | 2022 | | (In thousands of Euro, except per share amounts) | | | | | (Loss) / profit for the period | | (75,102 ) | 54,513 | | Items that may be reclassifi ...

Revenue and Financial Performance - Revenue increased by €97.5 million, from nil for the year ended December 31, 2021 to €97.5 million for the year ended December 31, 2022, driven by the Menarini License upfront payment[605]. - The company reported a loss before tax of €78.1 million for the year ended December 31, 2022, compared to a loss of €28.6 million in 2021[604]. - Loss for the year increased by €49.5 million, from a loss of €28.6 million in 2021 to a loss of €78.1 million in 2022, mainly due to increased research and development expenses and share listing expenses[618]. - As of December 31, 2022, the company had an accumulated loss of €119.4 million and expects to continue incurring significant losses in the foreseeable future[620]. - Cash as of December 31, 2022, was €438.5 million, which is expected to fund operations through 2026 based on the current operating plan[622]. Expenses - Research and development expenses rose significantly to €82.2 million in 2022, up from €25.0 million in 2021, reflecting increased clinical trial activities[604]. - Selling, general and administrative expenses increased to €22.2 million in 2022 from €4.8 million in 2021, due to higher costs associated with being a public company[604]. - The total operating expenses for 2022 were €165.1 million, compared to €29.8 million in 2021, marking an increase of €135.2 million[604]. - Research and development expenses increased by €57.2 million, or 228%, from €25.0 million in 2021 to €82.2 million in 2022, primarily due to higher clinical trial costs[606]. - Selling, general and administrative expenses rose by €17.4 million, or 363%, from €4.8 million in 2021 to €22.2 million in 2022, driven by increased personnel and transaction costs[610]. - Share listing expenses amounted to €60.6 million in 2022, resulting from the Business Combination, reflecting the excess of the fair value of equity instruments issued over the fair value of net assets contributed[612]. Research and Development - Obicetrapib demonstrated a 51% median lowering of LDL-C from baseline at a 10 mg dose level in the Phase 2b ROSE trial[583]. - The company expects research and development expenses to increase substantially as it advances obicetrapib through clinical trials[595]. - The company has partnered with Menarini for the commercialization of obicetrapib in most European countries, pending marketing approval[585]. Foreign Currency and Risk Exposure - As of December 31, 2022, the company's net exposure to foreign currency risk was €268.2 million, up from €15.9 million as of December 31, 2021[602]. - The company recognized significant foreign exchange losses in 2022 due to holding a substantial U.S. Dollar balance while its functional currency is Euro[857]. - Net foreign exchange losses decreased by €10.7 million, from a gain of €1.4 million in 2021 to a loss of €9.3 million in 2022, primarily due to the appreciation of the U.S. Dollar[615]. - For the year ended December 31, 2022, the U.S. Dollar depreciation by 10% resulted in a loss of €24,361 thousand before tax, while a 10% appreciation led to a gain of €29,775 thousand[859]. Financing Activities - The company completed a Business Combination with FLAC, resulting in gross proceeds of $306.3 million from the transaction and associated PIPE Financing, after deducting $2.6 million in transaction costs[632]. - The PIPE Financing involved the issuance of 23,460,000 Ordinary Shares at $10.00 per share, generating gross proceeds of $234.6 million[631]. - The company reported net cash flows from financing activities of €375.2 million for the year ended December 31, 2022, compared to €69.0 million in 2021, reflecting the impact of the Business Combination[639]. Contractual Obligations and Liabilities - The company has estimated maximum contractual obligations of €16.6 million due within one year and €5.1 million due in more than a year related to third-party service agreements[640]. - As of December 31, 2022, derivative warrant liabilities amounted to €3.9 million and derivative earnout liability was €7.1 million[860]. - The company is responsible for 50% of certain development costs incurred by Menarini in the development of Licensed Products in the Menarini Territory[646]. - The company has not included potential cash proceeds from the exercise of Warrants in its liquidity projections, indicating uncertainty regarding their exercise[634]. Other Financial Information - For the year ended December 31, 2022, net cash provided by operating activities was €8.0 million, a significant improvement of €33.1 million compared to a net cash outflow of €25.2 million in 2021[635][636]. - A 15% increase in share price under derivative warrant liabilities (NAMSW) would decrease profit or loss before tax by €583 thousand, while a 15% decrease would increase it by the same amount[862]. - A 15% increase in share price under derivative earnout liability (NAMS) would decrease profit or loss before tax by €1,058 thousand, while a 15% decrease would increase it by the same amount[862]. - The company is exposed to credit risk primarily from treasury activities, with available cash held in banks with investment grade credit ratings[863]. - The CEO repaid a loan of €709 thousand on July 19, 2022, which was secured and bore interest[864]. - The company is currently engaged in research and development activities and does not have any sales, allowing it to reclaim recoverable Value Added Tax (VAT)[865].

Exhibit 99.1 NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update — Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 — — Announced positive topline results from ROSE2 Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high- intensity statin therapy; plan to ...